• GlucoTrack (GCTK) announced the pricing of an underwritten public offering of shares to the value of around $10 million dollars
  • The offer consists of 7,352,942 shares of common stock and pre-funded warrants at a price to the public of $1.36
  • New York-based Aegis Capital is the sole underwriter for the offering
  • Glucotrack is focused on easing glucose monitoring with a range of products focused on managing the needs of both Type 1 and Type 2 diabetes
  • GlucoTrack (GTCK) is down 50 per cent on the day with shares trading at US$1.37

GlucoTrack (GCTK) announced the pricing of an underwritten public offering of shares to the value of roughly $10 million dollars.

The offer consists of 7,352,942 shares of common stock and pre-funded warrants at a price of $1.36.

New York-based Aegis Capital is the sole underwriter for the offering. The offering is expected to close on April 17, 2023.

About GlucoTrack

GlucoTrack, is a medical device, and digital health platform company.

By narrowing in on diabetes and prediabetes the company hopes to use the net proceeds from this offering for working capital and general corporate purposes.

Glucotrack eases glucose monitoring with a range of products managing the needs of both Type 1 and Type 2 diabetes.

Additionally, the company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements.

The result is no pain or discomfort of conventional invasive finger stick devices and a reduction in cost.

GlucoTrack (GTCK) is down 50 per cent on the day, trading at US$1.37 at close.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here

More From The Market Online

Revolutionizing medical imaging with nanocarbon-based contrast drugs

The partnership between Rain Cage Carbon and Voyageur Pharmaceuticals (TSXV:VM) is transforming carbon capture and reuse technology.

Optimi Health completes first MDMA shipment to Israel

Optimi Health (CSE:OPTI) recently touted several milestones it had achieved in its international psychedelic supply operations strategy.

Theralase enhances cancer drug efficacy

Theralase Technologies (TSXV:TLT) announces its Ruvidar compound creates a new compound able to significantly kill more cancer cells.

FDA committee rejects MDMA drug, discounting psychedelic stocks

A committee of the U.S. FDA rejects a drug application to treat PTSD using MDMA-assisted therapy, causing numerous stocks to fall.